erlotinib、docetaxel和pemetrexed的经济评价

{"title":"erlotinib、docetaxel和pemetrexed的经济评价","authors":"S. Capri, A. Morabito, Guido Carillio, F. Grossi, R. Longo, Giulio Cerea, F. Rossetti","doi":"10.1007/BF03320705","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":187376,"journal":{"name":"PharmacoEconomics Italian Research Articles","volume":"161 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2007-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule\",\"authors\":\"S. Capri, A. Morabito, Guido Carillio, F. Grossi, R. Longo, Giulio Cerea, F. Rossetti\",\"doi\":\"10.1007/BF03320705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":187376,\"journal\":{\"name\":\"PharmacoEconomics Italian Research Articles\",\"volume\":\"161 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Italian Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF03320705\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Italian Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF03320705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}